Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Aug 08, 2022
Investor presentation, 8 August 2022
Aug 08, 2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Jul 29, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
Jul 19, 2022
Acadia submits Rett Syndrome New Drug Application to the FDA
Jul 12, 2022
Neuren commences Phase 2 trial of NNZ-2591 in Angelman
Jul 08, 2022
Notification regarding unquoted securities - NEU
Jul 08, 2022
Neuren appoints Chief Medical Officer in United States
May 30, 2022
Results of Meeting
May 30, 2022
AGM Chairman's Address & CEO Presentation
Apr 29, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
Previous
1
2
3
4
Next